Artimplant builds team ahead of first CE marking
This article was originally published in Clinica
Artimplant, a publicly-quoted Swedish orthopaedic company, is ramping up its sales force in anticipation of the CE marking of its first product, a biodegradeable anterior cruciate ligament implant, expected in May.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.